AI is about to change healthcare. These 6 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Nichias today, you need to believe in its ability to compound value from niche materials and components, with the Advanced Products Division riding structurally higher demand for semiconductor manufacturing equipment. The latest quarter, with rising sales, revenue and net income, and a completed ¥4,999.92 million buyback, reinforces a capital allocation story that already includes a long track record of profit growth and a reliable dividend. The raised full year guidance tied to AI-driven equipment demand strengthens the near term earnings catalyst, but it also increases Nichias’s exposure to a single, highly cyclical end market at a time when the share price has already delivered a very large three year total return. That makes the key risk today less about execution and more about how the cycle evolves from here.
However, investors should be aware of how concentrated the new guidance is on AI-related equipment demand. Nichias' shares are on the way up, but they could be overextended by 29%. Uncover the fair value now.Explore another fair value estimate on Nichias - why the stock might be worth as much as ¥2806!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com